RE: David Allmond from #NCYT?9 Nov 2023 10:51
Knowing the market space that NCYT operate in with extreme detail David Allmond as a more Pharma orientated C suite experienced individual may have been a poor move on both sides. However NCYT at the time he joined was a slow moving car crash as Covid was beginning to be over with testing locked out to the big guys in hospital market like roche, abbott and thermo and thermo got a lot of the lighthouse work, the test suite they had was a one trick pony and the regulatory overheads were massively increased with CTDA and that was a nightmare. They bought and marketed the IT-IS systems which are quite unloved by users and marketed falsely as point of care where they are clearly unsuited for this. The DHSC dispute could go either way but having put together a consortium bid to run and supply a lighthouse lab I am so grateful we lost that bid as the site ultimately never opened and the cost exposure would have left us with.multi million liabilities. They.may win their case, they have cash but have no real strategy and maybe there is a decent business hiding in their but investor base was a lot of new covid lockdown funds chasing the price and its ultimate high was fantasy land stuff valuation. Non of the share price decline is really attributable to DA and the current price is roughly fair.imho the days of over a quid for them long gone without real investment in product and certification and a decent outcome vs dhsc. DA may have been honest about what they needed to do, the rest of board disagreed and that may have led to leaving. Will be interesting in how the dynamic of DA and JS will develop.